PURPOSE OF REVIEW: Recent clinical trial results have indicated that it may be possible for vaccines to induce protection against HIV. To build on this result, strategies should be designed to enhance duration, breadth, and magnitude of antibody production. Strategic formulation of agonists of the innate immune system and carriers that selectively present the target antigen yields a class of pharmaceuticals, named 'adjuvants', that greatly influence immunity resulting from vaccination. As researchers begin to focus not only on creating an immune response to an antigen, but also on the quality of that response, the role of adjuvants is becoming increasingly significant. This review is intended to give an overview of recent findings on how adjuvants model the immune response to antigens with a focus on the field of vaccines for HIV. RECENT FINDINGS: It is clear that innate and adaptive immunity are linked by communication channels that allow innate signals to influence the quality of adaptive responses as well as adaptive signals that temper innate responses. Adjuvants take advantage of this bridge to shape the immune response to antigens. In this review, we will discuss the different classes of adjuvants currently available; recent findings on the relationship between adjuvants and the type of immune profile generated; and the breadth of neutralizing antibodies as influenced by adjuvants. SUMMARY: Because adjuvants influence the breadth of antibodies generated and the type of cells that proliferate in response to a vaccine this review is relevant for scientists clinicians involved in creating a new HIV vaccine.
PURPOSE OF REVIEW: Recent clinical trial results have indicated that it may be possible for vaccines to induce protection against HIV. To build on this result, strategies should be designed to enhance duration, breadth, and magnitude of antibody production. Strategic formulation of agonists of the innate immune system and carriers that selectively present the target antigen yields a class of pharmaceuticals, named 'adjuvants', that greatly influence immunity resulting from vaccination. As researchers begin to focus not only on creating an immune response to an antigen, but also on the quality of that response, the role of adjuvants is becoming increasingly significant. This review is intended to give an overview of recent findings on how adjuvants model the immune response to antigens with a focus on the field of vaccines for HIV. RECENT FINDINGS: It is clear that innate and adaptive immunity are linked by communication channels that allow innate signals to influence the quality of adaptive responses as well as adaptive signals that temper innate responses. Adjuvants take advantage of this bridge to shape the immune response to antigens. In this review, we will discuss the different classes of adjuvants currently available; recent findings on the relationship between adjuvants and the type of immune profile generated; and the breadth of neutralizing antibodies as influenced by adjuvants. SUMMARY: Because adjuvants influence the breadth of antibodies generated and the type of cells that proliferate in response to a vaccine this review is relevant for scientists clinicians involved in creating a new HIV vaccine.
Authors: Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff Journal: Vaccine Date: 2006-06-19 Impact factor: 3.641
Authors: Susan W Barnett; Brian Burke; Yide Sun; Elaine Kan; Harold Legg; Ying Lian; Kristen Bost; Fengmin Zhou; Amanda Goodsell; Jan Zur Megede; John Polo; John Donnelly; Jeffrey Ulmer; Gillis R Otten; Christopher J Miller; Michael Vajdy; Indresh K Srivastava Journal: J Virol Date: 2010-04-14 Impact factor: 5.103
Authors: Mei-Yun Zhang; Andrew Rosa Borges; Roger G Ptak; Yanping Wang; Antony S Dimitrov; S Munir Alam; Lindsay Wieczorek; Peter Bouma; Timothy Fouts; Shibo Jiang; Victoria R Polonis; Barton F Haynes; Gerald V Quinnan; David C Montefiori; Dimiter S Dimitrov Journal: MAbs Date: 2010-05-05 Impact factor: 5.857
Authors: Laurel A Lagenaur; Vadim A Villarroel; Virgilio Bundoc; Barna Dey; Edward A Berger Journal: Retrovirology Date: 2010-02-16 Impact factor: 4.602
Authors: Mushtaq Ahmed; Douglas M Smith; Tarek Hamouda; Javier Rangel-Moreno; Ali Fattom; Shabaana A Khader Journal: Vaccine Date: 2017-07-31 Impact factor: 3.641
Authors: Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi Journal: Eur J Immunol Date: 2011-12-12 Impact factor: 5.532
Authors: Joseph R Francica; Daniel E Zak; Caitlyn Linde; Emilio Siena; Carrie Johnson; Michal Juraska; Nicole L Yates; Bronwyn Gunn; Ennio De Gregorio; Barbara J Flynn; Nicholas M Valiante; Padma Malyala; Susan W Barnett; Pampi Sarkar; Manmohan Singh; Siddhartha Jain; Margaret Ackerman; Munir Alam; Guido Ferrari; Andres Salazar; Georgia D Tomaras; Derek T O'Hagan; Alan Aderem; Galit Alter; Robert A Seder Journal: Blood Adv Date: 2017-11-17
Authors: Yu Feng; Mattias N E Forsell; Barbara Flynn; William Adams; Karin Loré; Robert Seder; Richard T Wyatt; Gunilla B Karlsson Hedestam Journal: Virology Date: 2013-08-15 Impact factor: 3.616
Authors: Virginie Jakob; Livia Brunner; Christophe Barnier-Quer; Molly Blust; Nicolas Collin; Lauren Carter; Darrick Carter; Kelly M Rausch; Christopher B Fox Journal: Ther Adv Vaccines Date: 2017-05-03
Authors: Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui Journal: Expert Rev Vaccines Date: 2016-01-13 Impact factor: 5.217
Authors: Weidong Zhang; Gul Ahmad; Loc Le; Juan U Rojo; Souvik Karmakar; Kory A Tillery; Workineh Torben; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui Journal: Parasitol Res Date: 2014-04-12 Impact factor: 2.289